<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Internal Medicine: Suicide Topic Collection</title>
    <link>http://archinte.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Mon, 10 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:52:17 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archinte.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archinte.jamanetwork.com</webMaster>
    <item>
      <title>The FDA and New Safety Warnings</title>
      <link>http://archinte.jamanetwork.com/article.aspx?articleID=1108624</link>
      <pubDate>Mon, 09 Jan 2012 00:00:00 GMT</pubDate>
      <author>Moore TJ, Singh S, Furberg CD. </author>
      <description>&lt;span class="paragraphSection"&gt;In response to postmarket drug safety surveillance and research data, the US Food and Drug Administration (FDA) and drug manufacturer may take 1 of 2 types of action. In extreme cases the FDA may remove a drug from the market. More often the product label or package insert is revised to reflect newly discovered risks. The most clinically significant new information is added to 1 of 3 legally defined sections of the prescribing information: (1) a boxed warning (information that is essential to be considered when prescribing the drug); (2) a contraindication (clinical situations when a drug's risks clearly outweigh its benefits); and (3) a warning (adverse reactions with reasonable evidence of a causal association, reactions that may require discontinuation, or reactions that interfere with a laboratory test).&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">172</prism:volume>
      <prism:number xmlns:prism="prism">1</prism:number>
      <prism:startingPage xmlns:prism="prism">78</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">80</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archinternmed.2011.618</prism:doi>
      <guid>http://archinte.jamanetwork.com/article.aspx?articleID=1108624</guid>
    </item>
    <item>
      <title>What Is Professionalism?</title>
      <link>http://archinte.jamanetwork.com/article.aspx?articleID=1108666</link>
      <pubDate>Mon, 23 Jan 2012 00:00:00 GMT</pubDate>
      <author>Finestone AJ. </author>
      <description>&lt;span class="paragraphSection"&gt;In reading the Special Article in the August 8/22, 2011, issue of the Archives, with the subtitle “Meeting the Responsibility of Professionalism” it appeared to me that this was a subject of quality performance. As defined in the dictionary, professionalism is the conduct, aims, or qualities that characterize or mark a profession or a professional person. General rules of behavior apply to all professions. In medicine these qualities are particularly compelling because much of our fees involve outside organizations including the federal government. A relevant article was recently published addressing this subject as well as health care reform, of vital interest to both our profession and the public. This bill has now been passed but is subject to court challenges. In my view, professionalism for a physician means placing the interests of the patient ahead of his or her own interests, including financial interests. Many individual physicians support this bill, but in my opinion medical professional organizations are not enthusiastic about or in support of cost-cutting measures that will affect their income.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">172</prism:volume>
      <prism:number xmlns:prism="prism">2</prism:number>
      <prism:startingPage xmlns:prism="prism">197</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">197</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archinte.172.2.197-a</prism:doi>
      <guid>http://archinte.jamanetwork.com/article.aspx?articleID=1108666</guid>
    </item>
  </channel>
</rss>